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Abstract
Parkinson's disease (PD) is the most common neurodegenerative movement disorder that affects
about 1% of the population worldwide. Despite significant advances in the identification of genetic
mutations and signaling pathways that are associated with the disease, the precise mechanisms
implicated in the pathophysiology of the disease are not well understood. More importantly,
treatments that are effective in reversing the progression of the disease is essentially lacking.
Further investigation into the pathogenic mechanisms of PD thus presents a pressing concern for
neuroscientists. Recently, deregulation of the autophagic pathway is observed in the brains of PD
patients and in models of PD. In this review we summarize current literature on the emerging
involvement of autophagy in PD, and the implication for future development of treatment against
the disorder.
Introduction
Parkinson's disease is a neurodegenerative disorder char-
acterized by the degeneration of neurons in the substantia
nigra pars compacta of the brain. On a cellular level, neu-
ronal loss is accompanied by neurite degeneration and the
presence of cytoplasmic inclusions known as Lewy bod-
ies. PD is the most common neurodegenerative move-
ment disorder and the second most common
neurodegenerative disease, with the prevalence rising
from 1% at age 65 to about 4-5% at age 85 [1]. Most of the
PD cases are sporadic, although familial PD with auto-
somal dominant or autosomal recessive mutations also
account for about 5% of all PD cases [2]. PD patients suf-
fer from resting tremor, bradykinesia, muscle rigidity and
postural instability. While the deterioration of motor
functions observed in PD patients is predominantly
attributable to the degeneration of dopaminergic neurons
in the substantia nigra, neuron loss in other brain regions,
including locus ceruleus and raphe nucleus, are also
observed in post-mortem brains of PD patients [3].
Despite the prevalence of the disease, current treatment
only ameliorates symptoms by attempting to reverse
dopaminergic deficits. Extensive effort has therefore been
directed at explicating the pathogenic mechanisms of PD,
in hope of identifying targets that would enable reduction
of neuronal loss and halting of disease progression. Vari-
ous pathogenic mechanisms have been associated with
neuronal loss in PD, including oxidative stress, mitochon-
drial dysfunction, protein aggregation and abnormality
with the ubiquitin-proteasome pathway [3]. In particular,
identification of autosomal dominant and autosomal
recessive mutations in cases of familial PD has signifi-
cantly contributed to our current understanding of the
pathogenesis of PD. For example, autosomal dominant
A53T and A30P mutation of alpha-synuclein, the main
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[4,5]. Interestingly, mutant alpha-synucleins are more
prone to oligomerization [6]. Furthermore, increased
gene dosage of alpha-synuclein is associated with certain
cases of familial PD [7,8]. These observations point to a
pivotal involvement of alpha-synuclein and protein
aggregation in the pathogenesis of PD. Presence of protein
aggregates in PD brains could also be attributed to dereg-
ulation of the ubiquitin-proteasome degradation system.
Mutations in Parkin, an ubiquitin E3-ligase, and ubiqui-
tin-C-terminal hydrolase-L1 (UCH-L1), a protein that is
involved in the degradation of poly-ubiquitin chains, are
both associated with familial PD cases [9,10]. On the
other hand, evidence in support of a role of mitochondrial
dysfunction in PD came from the identification of muta-
tions in PINK1 and Parkin, both of which have been dem-
onstrated to regulate mitochondrial morphology and
function [11,12].
Interestingly, recent studies reveal that deregulation of
autophagy is evident in the brains of PD patients [3].
Indeed, the autophagic pathway is increasingly implicated
in a number of neurodegenerative diseases [13]. In the fol-
lowing sections, we summarize existing knowledge on the
role of autophagy in PD.
The autophagic pathway
Autophagy is traditionally considered as a cellular home-
ostatic process pivotal for bulk degradation of cytoplas-
mic contents and organelles. Aside from the ubiquitin-
proteasome degradation pathway, which is involved
mainly in the breakdown of short-lived proteins, the
autophagic pathway represents the other major mecha-
nism by which intracellular proteins are degraded. The
autophagic pathway is responsible for the degradation of
long-lived proteins, protein aggregates and cytoplasmic
organelles [14]. Degradation of proteins and organelles
begin with the sequestration of cargo into various vesicles
of the autophagic pathway. Based on the mechanisms by
which cargos enter the autophagic pathway, 3 different
forms of autophagy have been identified: macroau-
tophagy, microautophagy and chaperone-mediated
autophagy (CMA). Macroautophagy is probably the best
characterized form of autophagy among the three. Seques-
tration of cargo begins with the formation of a double-
membraned structure known as the autophagosome. Car-
gos are either sequestered through bulk engulfment of the
cytoplasmic content, or through selective targeting. Con-
tent of the autophagosomes are then degraded through
fusion with lysosomes, leading to the formation of
autolysosomes [13,15]. Microautophagy is similar to
macroautophagy in that cargos enter the autophagic path-
way through direct sequestration of cellular contents, but
cargos are sequestered directly into the lysosomes instead
of the autophagosomes [13]. On the other hand, CMA is
distinct from macroautophagy and microautophagy in
several aspects. First of all, instead of sequestration of
cargo through bulk engulfment of cytoplasmic contents,
proteins destined for CMA usually contain a targeting
motif KFERQ and are selectively translocated into the
autophagic pathway. Secondly, CMA is predominantly
involved in the degradation of soluble proteins. Proteins
targeted for CMA are recognized by cytosolic chaperone
heat-shock cognate 70 (Hsc70), followed by transporta-
tion directly into the lysosomes through association with
lysosomes-associated membrane protein 2A (LAMP2A)
[13,14]. Figure 1 summarizes the various types of
autophagy.
Deregulation of the autophagic pathway in PD
Given the role of the autophagic pathway as a degradation
system for clearance of aggregated proteins, it is not sur-
prising that autophagic deregulation observed in various
neurodegenerative disorders has attracted mounting inter-
ests. For example, accumulation of autophagosomes are
evident in the brains of Alzheimer's disease patients [13].
Indeed, protein aggregates presents one of the common
features in a myriad of neurodegenerative diseases,
including the β-amyloid plagues in Alzheimer's disease,
mutant huntingtin cytoplasmic inclusions in Hunting-
ton's disease, and the alpha-synuclein containing Lewy
bodies in PD. While the role of these protein aggregates in
the pathogenesis of these disorders remain controversial,
it is plausible that removal of protein aggregates through
activation of the autophagic pathway would interfere with
the potential toxicity of these aggregates, thereby alleviat-
ing disease progression. Indeed, accumulating evidence
supports a protective role of autophagy through clearance
of protein aggregates. For example, reduction of hunting-
tin aggregates in a model of Huntington's disease through
activation of macroautophagy limits neuronal loss and
behavioral deficits [16]. Furthermore, knock down of
autophagy-related (ATG) genes, molecular players that are
pivotal for the induction and execution of macroau-
tophagy, results in neurodegeneration and the presence of
cytoplasmic inclusions filled with ubiquitinated proteins
[17,18]. These observations suggest that basal level of
autophagy is important for the clearance of protein aggre-
gates, and the reduction of cytoplasmic inclusions may be
protective against neurodegenerative diseases. Nonethe-
less, excessive activation of the autophagic pathway has
also been associated with cell death [15]. It is therefore
pivotal to delineate the precise involvement of autophagy
in the pathogenesis of neurodegenerative diseases.
Autophagy as a protective mechanism in PD
One of the first evidence in support of an important role
of autophagy in PD came from the demonstration that
alpha-synuclein is degraded by macroautophagy and
CMA [19-21]. Since alpha-synuclein is the major constit-Page 2 of 6
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both sporadic and familial cases of PD, it is important to
delineate the mechanisms by which alpha-synuclein is
degraded. Interestingly, while the ubiquitin-proteasome
pathway and macroautophagy are both implicated in the
clearance of alpha-synuclein, CMA was found to be essen-
tial for the degradation of wildtype alpha-synuclein [19-
21]. Furthermore, inhibition of CMA results in the forma-
tion of high molecular weight and detergent-insoluble
species of alpha-synuclein [21], revealing that in healthy
neurons, clearance of alpha-synuclein by CMA is crucial
for limiting the oligomerization of alpha-synuclein.
Importantly, A53T and A30P mutants of alpha-synuclein,
which cause familial PD, were found to inhibit CMA
through exhibiting a higher affinity for LAMP2A [20].
Nonetheless, alpha-synuclein mutants are poorly inter-
nalized into lysosomes, and are degraded by macroau-
tophagy instead of CMA. Accompanying the inhibition of
CMA by alpha-synuclein mutants is a compensatory acti-
vation of macroautophagy, although the physiological
significance of this event is incompletely understood.
Nonetheless, these observations suggest that A53T and
A30P alpha-synuclein mutants may induce alpha-synu-
clein aggregation through inhibition of CMA, thereby
Implication of autophagy deregulation in Parkinson's disease (PD)Figure 1
Implication of autophagy deregulation in Parkinson's disease (PD). There are 3 types of autophagy: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA). See text for detailed description of the different types of 
autophagy. Deregulation of both macroautophagy and CMA are implicated in the pathogenesis of PD. CMA is involved in the 
degradation of soluble wildtype alpha-synuclein, the major constituent of Lewy bodies. Nonetheless, once oligomerized or 
aggregated, alpha-synuclein is likely degraded by macroautophagy instead of CMA. Interestingly, A53T and A30P mutants of 
alpha-synuclein are poorly degraded by CMA, but are instead degraded by macroautophagy. Furthermore, the alpha-synuclein 
mutants inhibit CMA, reducing CMA-mediated degradation of alpha-synuclein and survival factor MEF2D. Concomitant with 
the inhibition of CMA, overexpression of alpha-synuclein mutants results in a compensatory activation of macroautophagy. 
Activation of macroautophagy is also evident in cells treated with neurotoxin MPP+, a well-established model for Parkinsonism, 
or following overexpression of GPR37, another protein that is present in Lewy bodies. Finally, recent studies reveal that mac-
roautophagy also plays a role in the turnover of fragmented mitochondria. These observations highlight the potential involve-
ment of the autophagic pathways in the pathogenesis of PD.Page 3 of 6
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On the other hand, 193M missense mutation in UCH-L1,
which was previously identified in familial cases of PD, is
also implicated in the regulation of CMA [22]. They found
that mutant UCH-L1 exhibits an abnormally high affinity
towards key players in the CMA pathway, such as LAMP2A
and Hsc70. More importantly, overexpression of UCH-L1
mutant increases alpha-synuclein level [22], suggesting
that UCH-L1 mutation may also contribute to PD pathol-
ogy through regulating alpha-synuclein levels. These find-
ings reveal that inhibition of CMA-mediated degradation
of alpha-synuclein may constitute an important patho-
genic mechanism for PD.
Interestingly, it was recently demonstrated that alpha-
synuclein may also contribute to neuronal death in PD
through inhibiting CMA-mediated degradation of sur-
vival factor MEF2D [23]. Both wildtype and A53T mutant
of alpha-synuclein interfere with the binding of MEF2D to
CMA machinery Hsc70. Consistent with this observation,
MEF2D level is elevated in A53T alpha-synuclein trans-
genic mice, and also in PD patients. Furthermore, overex-
pression of both wildtype and A53T mutant of alpha-
synuclein inhibit MEF2 activity, and result in neuronal
death [23]. These observations reveal that in addition to
alpha-synuclein, impaired CMA may also trigger neuronal
death through inefficient degradation of other proteins.
These findings collectively raise the interesting possibility
that preservation of CMA functions may serve as an effec-
tive treatment against PD.
Aside from the degradation of alpha-synuclein, the
autophagic pathway is also involved in the turnover of
mitochondria. Mitochondrial dysfunction presents one of
the pathogenic mechanisms in PD. In particular, deficits
in the mitochondrial complex I is observed in PD
patients. Furthermore, MPTP, the neurotoxin that gener-
ates PD symptoms in human through selective degenera-
tion of dopaminergic neurons in the substantia nigra,
functions as a complex I inhibitor after it is converted into
MPP+ [3]. More importantly, mutations identified from
cases of familial PD have been mapped to Parkin and
PINK1, two proteins that are implicated in the control of
mitochondrial morphology and function [11,12]. Muta-
tion in these two proteins presumably leads to loss of
function, thus resulting in mitochondrial abnormality.
Recently, Parkin was found to facilitate macroautophagy
of impaired mitochondria, a process that is also known as
mitophagy [24]. Parkin is selectively targeted to mito-
chondria that are impaired, characterized by a low mito-
chondrial transmembrane potential, which are then
eliminated by macroautophagy [24]. In support of a role
of autophagy in the clearance of defective mitochondria
in PD, knock down of PINK1 expression induces mito-
chondrial fragmentation, followed by activation of
autophagy/mitophagy [25]. These observations suggest
that the autophagic pathway is essential for the turnover
of dysfunctional mitochondria in PD. Failure to activate
efficient mitophagy may serve as a pathogenic mechanism
of PD.
Could excessive activation of the autophagic pathway 
lead to cell loss?
Despite mounting observations that are in support of a
protective role of autophagy in various models of PD, one
essential question remains unanswered. While it is per-
ceivable that insufficient autophagy activation would
impair clearance of protein aggregates and dysfunctional
mitochondria, whether excessive activation of autophagy
happens in PD, and whether it plays a role in PD pathol-
ogy remains unknown. This question is particularly
important since excessive activation of autophagy is asso-
ciated with neuronal loss [15]. Indeed, abnormal presence
of autophagic vacuoles is evident in the brains of PD
patients, in contrast to the rare detection of autophago-
somes in normal brain, due to the rapid clearance of these
vesicles in the central nervous system [26,27]. The pres-
ence of autophagosomes in PD brains could represent
aberrant activation of macroautophagy, although defec-
tive clearance of the autophagic vacuoles could also
account for this observation. While there is little evidence
to delineate the two possibilities, in vitro findings reveal
that macroautophagy can be induced by players associ-
ated with PD pathology. For example, as mentioned pre-
viously, overexpression of alpha-synuclein mutants
results in activation of macroautophagy [20,21]. Aside
from alpha-synuclein, GPR37, another protein that is
present in Lewy bodies, is also recently demonstrated to
induce macroautophagy [28]. Furthermore, treatment
with MPP+ has also been observed to increase autophagic
vacuole contents [29]. Clearly, a question that urgently
needs to be addressed is whether the induction of macro-
autophagy results in cell death. Several studies provided
evidence that overexpression of A53T mutant of alpha-
synuclein in PC12 cells, cultured neurons and the nigros-
triatal systems results in autophagic cell death [23,30-32].
These studies indicate that while activation of macroau-
tophagy may serve as a protective machinery, excessive
activation could result in neuronal death and hence also
contribute to cell loss in PD.
Conclusion
Given the lack of effective treatment targeted at halting
disease progression and neuronal loss in PD, advances in
the development of novel therapeutic strategy would rely
on a better understanding of the pathogenic mechanisms
of PD. Mounting evidence suggests that the autophagic
pathway is emerging as a key pathway for regulating the
pathogenesis of PD. Nonetheless, as mentioned above
(Figure 1), whether activation of autophagy serves a ben-Page 4 of 6
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Since autophagy is part of the cell's homeostatic machin-
ery, basal autophagic activity would undoubtedly be
important for minimizing abnormal protein aggregation
and for facilitation of organelle turnover. Maintaining
autophagic activity at a certain level is particularly impor-
tant since the level of macroautophagy and CMA are both
observed to decrease with age [33]. Development of ther-
apeutic agents that boost autophagic response could thus
serve as a strategy to combat protein aggregation in PD,
and also in other neurodegenerative diseases with cyto-
plasmic inclusions. Nonetheless, since excessive activa-
tion of the autophagic pathway leads to cell death,
designing a drug that would only activate autophagy to a
certain optimal extent would be essential, albeit extremely
challenging. Ultimately, more physiologically relevant
evidence on the activation status of the autophagic path-
way in PD patients would be required to determine if acti-
vation or suppression of autophagy would be most
effective in ameliorating PD symptoms and delaying dis-
ease progression. Future studies aiming at resolving the
existing controversy would be pivotal in turning these
findings into effective treatment against PD.
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